Please use this identifier to cite or link to this item:
Type: Conference item
Title: Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint
Author: Branford, S.
Ross, D.
Yeung, D.
Braley, J.
Hughes, T.
Citation: Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 2014 / vol.124, iss.21, pp.4561
Publisher: American Society of Hematology
Issue Date: 2014
ISSN: 0006-4971
Conference Name: 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
Statement of
Susan Branford, David M Ross, David T Yeung, Jodi Braley, and Timothy P. Hughes
Rights: © 2014 by The American Society of Hematology
RMID: 0030023654
Published version:
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.